San Diego-primarily based Viking Therapeutics marked itself as a serious competitor inside the weight loss drug market in February immediately after revealing promising details from the mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection and in Ma